About 4,455 results

ALLMedicine™ Calcitonin Gene-related Peptide Center

Research & Reviews  1,527 results

Cardiovascular Disease and Migraine: Are the New Treatments Safe?
https://doi.org/10.1007/s11916-022-01064-4 10.3389/fncel.2018.00233 10.1080/14728222.2020.1724285 10.1111/j.1526-4610.2012.02274.x 10.1016/j.npep.2010.12.002 10.1016/S0008-6363(98)00016-9 10.1177/0333102419863027 10.1177/0333102419867282 10.1177/0333102414547138 10.1136/jnnp-2018-318254 10.1111/head.14001 10.1136/bmj.a636 10.1177/0333102414559551 10.3988/jcn.2021.17.2.164 10.1007/s10072-018-3429-8 10.1136/jnnp.2003.019638 10.1212/WNL.0b013e3181d0cc8b 10.1046/j.1365-2125.1999.00851.x 10.1067/mcp.2000.110502 10.1212/01.WNL.0000110312.36809.7F 10.1111/head.13959 10.1007/s00228-002-0482-1 10.1016/j.clpt.2006.03.011 10.1002/ana.410330109 10.1007/s10194-008-0011-4 10.1111/j.1468-2982.2008.01578.x 10.1177/0333102414544977 10.5505/tjtes.2014.43433 10.1177/1941874418797764 10.1212/WNL.0000000000004108 10.1016/j.pharmthera.2018.01.005 10.1111/bph.14832 10.1038/sj.bjp.0703081 10.1097/j.pain.0000000000001801 10.1186/s10194-020-01138-x 10.1016/j.clinthera.2021.04.004 10.1186/s10194-019-1044-6 10.1002/cpdd.768 10.1111/j.1365-2125.2010.03869.x 10.1177/0333102419884943 10.1002/ana.25831 10.1111/j.1526-4610.2011.02052.x 10.1038/clpt.2011.246 10.1016/S0140-6736(20)32544-7 10.1016/S0140-6736(19)31606-X 10.1177/0333102413500727 10.1056/NEJMoa2035908 10.1016/S1474-4422(20)30234-9 10.1177/03331024211000311 10.1002/cpt.1696 10.1111/head.13862 10.1111/head.14095 10.1111/head.13930 10.1016/S1474-4422(20)30279-9 10.1212/WNL.0000000000009169 10.1177/0333102418759786 10.1056/NEJMoa1705848 10.1016/S0140-6736(18)32534-0 10.1016/S1474-4422(17)30083-2 10.1177/0333102419854082 10.1001/jama.2018.4853 10.1056/NEJMoa1709038 10.1016/S0140-6736(19)31946-4 10.1001/jamaneurol.2018.1212 10.1177/0333102418779543 10.1212/WNL.0000000000006640 10.1111/head.13684 10.1177/0333102420905132 10.1007/s40259-021-00469-8 10.1111/head.13589 10.1212/WNL.0000000000010600 10.1186/s12883-018-1193-2 10.1186/s10194-020-01186-3 10.1186/s10194-020-01193-4 10.1111/head.13414 10.1177/0333102420983292 10.1212/WNL.0000000000010740 10.1186/s10194-017-0807-1
Current Pain and Headache Reports; Robblee J, Harvey LK

Jun 26th, 2022 - The authors present data on cardiovascular safety for the new acute and preventive migraine treatments including ditans, gepants, and calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) alongside older medications like triptans and e...

San Pian decoction can treat nitroglycerin-induced migraine in rats by inhibiting the P...
Journal of Ethnopharmacology; Mao Q, Cui Y et. al.

Jun 24th, 2022 - San Pian decoction (SPD), a traditional Chinese medicine preparation composed of eight herbs, has been reported to alleviate migraine. However, its active ingredients and the potential mechanism of action remains unclear. The purpose of this study...

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Jun 22nd, 2022 - Headache is recognized as one of the most common and disabling symptoms following head trauma. This study is designed to assess a calcitonin gene-related peptide (cGRP) monoclonal antibody (erenumab) for the preventive treatment of PTH based on th...

Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patie...
https://doi.org/10.1007/s00228-022-03347-6 10.1177/0333102416657147 10.1016/S1474-4422(17)30435-0 10.1046/j.1468-2982.1992.1204221.x 10.1016/j.pharmthera.2020.107528 10.1111/j.1526-4610.2004.04106.x 10.1186/s10194-019-1038-4 10.1016/j.ejphar.2022.174902 10.3969/j.issn.1673-5374.2013.10.009 10.1111/papr.12158 10.3109/00207454.2015.1137915 10.3389/fphar.2019.01577 10.1111/head.13858 10.1002/brb3.1701 10.1007/s40263-020-00715-7 10.1007/s40261-020-00997-1 10.1080/14737167.2021.1945444 10.1097/MD.0000000000024741 10.1111/j.1526-4610.2011.02052.x 10.1056/NEJMoa1813049 10.1056/NEJMoa1811090 10.1177/0333102410388435 10.1177/0333102411398399 10.1111/j.1526-4610.2011.01860.x 10.1212/WNL.0b013e3181b87942 10.1177/0333102410370878 10.1016/S0140-6736(08)61626-8 10.1111/j.1526-4610.2010.01799.x 10.1212/01.WNL.0000286940.29755.61 10.1016/S0140-6736(19)31606-X 10.1177/0333102413500727 10.1177/0333102416653233 10.1001/jama.2019.16711 10.1007/164_2018_201 10.1016/j.ncl.2019.07.008 10.1080/17434440.2019.1695599 10.2165/11630590-000000000-00000 10.1001/jamanetworkopen.2021.28544 10.3102/1076998609346961
European Journal of Clinical Pharmacology; Lee S, Staatz CE et. al.

Jun 22nd, 2022 - Calcitonin gene-related peptide (CGRP) receptor antagonists have been suggested as novel treatments for acute migraine. This study aimed to use meta-analysis to compare the safety and tolerability of five existing oral CGRP receptor antagonists (B...

see more →

Guidelines  1 results

European headache federation guideline on the use of monoclonal antibodies acting on th...
The Journal of Headache and Pain; Sacco S, Bendtsen L et. al.

Jan 18th, 2019 - Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and thr...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  55 results

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Jun 22nd, 2022 - Headache is recognized as one of the most common and disabling symptoms following head trauma. This study is designed to assess a calcitonin gene-related peptide (cGRP) monoclonal antibody (erenumab) for the preventive treatment of PTH based on th...

Transcranial Direct Current Stimulation Plus Monoclonal Antibodies Acting on the CGRP Pathway for Migraine

May 20th, 2022 - Electrophysiological changes that occur in the brains of migraine patients, lead to the activation of nociceptive centers, including a peripheral neural structure, the trigeminal ganglion (TG), which releases pain-inducing peptides and mostly calc...

Human Electrophysiological Model to Quantify the CGRP-related Axon Reflex of Trigeminal Afferents

May 18th, 2022 - The proposed project aims at establishing a neurophysiological biomarker for migraine. Migraine is one of the world's most disabling diseases and its prophylactic treatment is time and cost-consuming. Since each patient responds differently and un...

Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

May 6th, 2022 - TNP are a considerable burden and affects significantly the quality of life of the sufferer. There are medications for their management but while they may work for some patients, may not work for the others; in addition, side effects may be presen...

Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

May 6th, 2022 - Introduction: Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CGRP-R) are an effective option for the preventative treatment in episodic and chronic migraine. All monoclonal antibodies against CGRP or CGRP-R h...

see more →

News  193 results

More Positive Phase 3 Results 'Raise the Bar' for Migraine Drug

Jun 23rd, 2022 - Atogepant, a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist approved last year for migraine, is superior to placebo not only in terms of a 50% or greater responder rate but also for a 75% or greater and 100% responder ra...

Bariatric surgery can be a tool to relieve migraine
Randy Dotinga

Jun 20th, 2022 - DENVER – More than a weight-loss operation, bariatric surgery can also relieve migraine, possibly because of links between head pain and the gut, a neurologist told colleagues at the annual meeting of the American Headache Society. “There’s eviden.

Migraine relief in 20 minutes using eyedrops?
MDedge Family Medicine; Yufei Ge, MD, Gregory Castelli, PharmD, BCPS, BC-ADM

Jun 15th, 2022 - ILLUSTRATIVE CASE A 35-year-old woman with no significant past medical history presents for follow-up of migraine. At the previous visit, she was prescribed sumatriptan for abortive therapy.

Clinical Edge Journal Scan Commentary: Migraine June 2022
Thomas Berk, MD

Jun 3rd, 2022 - Many of our patients with refractory migraine do not respond to first-line acute or preventive treatments, and, almost by definition, first- and second-line treatments have failed in the majority of patients on calcitonin gene-related peptide (CGR.

Safety Concerns with CGRP Monoclonal Antibodies
Lawrence Robbins, MD

May 9th, 2022 - Editors’ note: For the April edition of Expert Perspectives, we asked 2 leading neurologists to present differing views on the use of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for the treatment of migraine. Here, Lawrence.

see more →